Cargando…
Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy
Lung cancer is one of the most common malignancies with a high rate of mortality. Lung cancer stem-like cells (CSCs)/ cancer-initiating cells (CICs) play major role in resistance to treatments, recurrence and distant metastasis and eradication of CSCs/CICs is crucial to improve recent therapy. Cytot...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332062/ https://www.ncbi.nlm.nih.gov/pubmed/28248963 http://dx.doi.org/10.1371/journal.pone.0171460 |
_version_ | 1782511483921367040 |
---|---|
author | Horibe, Ryota Hirohashi, Yoshihiko Asano, Takuya Mariya, Tasuku Suzuki, Takeshi Takaya, Akari Saijo, Hiroshi Shionoya, Yosuke Kubo, Terufumi Nakatsugawa, Munehide Kanaseki, Takayuki Tsukahara, Tomohide Watanabe, Kazue Atsuyama, Eri Toji, Shingo Hirano, Hiroshi Hasegawa, Tadashi Takahashi, Hiroki Sato, Noriyuki Torigoe, Toshihiko |
author_facet | Horibe, Ryota Hirohashi, Yoshihiko Asano, Takuya Mariya, Tasuku Suzuki, Takeshi Takaya, Akari Saijo, Hiroshi Shionoya, Yosuke Kubo, Terufumi Nakatsugawa, Munehide Kanaseki, Takayuki Tsukahara, Tomohide Watanabe, Kazue Atsuyama, Eri Toji, Shingo Hirano, Hiroshi Hasegawa, Tadashi Takahashi, Hiroki Sato, Noriyuki Torigoe, Toshihiko |
author_sort | Horibe, Ryota |
collection | PubMed |
description | Lung cancer is one of the most common malignancies with a high rate of mortality. Lung cancer stem-like cells (CSCs)/ cancer-initiating cells (CICs) play major role in resistance to treatments, recurrence and distant metastasis and eradication of CSCs/CICs is crucial to improve recent therapy. Cytotoxic T lymphocytes (CTLs) are major effectors of cancer immunotherapy, and CTLs recognize antigenic peptides derived from antigens that are presented by major histocompatibility complex (MHC) class I molecules. In this study, we analyzed the potency of a cancer-testis (CT) antigen, brother of the regulator of the imprinted site variant subfamily 6 (BORIS sf6), in lung CSC/CIC immunotherapy. BORIS sf6 mRNA was expressed in lung carcinoma cells (9/19), especially in sphere-cultured lung cancer stem-like cells, and in primary lung carcinoma tissues (4/9) by RT-PCR. Immunohistochemical staining using BORIS sf6-specific antibody revealed that high expression of BORIS sf6 is related to poorer prognosis. CTLs could be induced by using a human leukocyte antigen, (HLA)-A2 restricted antigenic peptide (BORIS C34_24(9)), from all of 3 HLA-A2-positive individuals, and CTL clone cells specific for BORIS C34_24(9) peptide could recognize BORIS sf6-positive, HLA-A2-positive lung carcinoma cells. These results indicate that BORIS sf6 is a novel target of lung cancer immunotherapy that might be useful for targeting treatment-resistant lung cancer stem-like cells. |
format | Online Article Text |
id | pubmed-5332062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-53320622017-03-10 Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy Horibe, Ryota Hirohashi, Yoshihiko Asano, Takuya Mariya, Tasuku Suzuki, Takeshi Takaya, Akari Saijo, Hiroshi Shionoya, Yosuke Kubo, Terufumi Nakatsugawa, Munehide Kanaseki, Takayuki Tsukahara, Tomohide Watanabe, Kazue Atsuyama, Eri Toji, Shingo Hirano, Hiroshi Hasegawa, Tadashi Takahashi, Hiroki Sato, Noriyuki Torigoe, Toshihiko PLoS One Research Article Lung cancer is one of the most common malignancies with a high rate of mortality. Lung cancer stem-like cells (CSCs)/ cancer-initiating cells (CICs) play major role in resistance to treatments, recurrence and distant metastasis and eradication of CSCs/CICs is crucial to improve recent therapy. Cytotoxic T lymphocytes (CTLs) are major effectors of cancer immunotherapy, and CTLs recognize antigenic peptides derived from antigens that are presented by major histocompatibility complex (MHC) class I molecules. In this study, we analyzed the potency of a cancer-testis (CT) antigen, brother of the regulator of the imprinted site variant subfamily 6 (BORIS sf6), in lung CSC/CIC immunotherapy. BORIS sf6 mRNA was expressed in lung carcinoma cells (9/19), especially in sphere-cultured lung cancer stem-like cells, and in primary lung carcinoma tissues (4/9) by RT-PCR. Immunohistochemical staining using BORIS sf6-specific antibody revealed that high expression of BORIS sf6 is related to poorer prognosis. CTLs could be induced by using a human leukocyte antigen, (HLA)-A2 restricted antigenic peptide (BORIS C34_24(9)), from all of 3 HLA-A2-positive individuals, and CTL clone cells specific for BORIS C34_24(9) peptide could recognize BORIS sf6-positive, HLA-A2-positive lung carcinoma cells. These results indicate that BORIS sf6 is a novel target of lung cancer immunotherapy that might be useful for targeting treatment-resistant lung cancer stem-like cells. Public Library of Science 2017-03-01 /pmc/articles/PMC5332062/ /pubmed/28248963 http://dx.doi.org/10.1371/journal.pone.0171460 Text en © 2017 Horibe et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Horibe, Ryota Hirohashi, Yoshihiko Asano, Takuya Mariya, Tasuku Suzuki, Takeshi Takaya, Akari Saijo, Hiroshi Shionoya, Yosuke Kubo, Terufumi Nakatsugawa, Munehide Kanaseki, Takayuki Tsukahara, Tomohide Watanabe, Kazue Atsuyama, Eri Toji, Shingo Hirano, Hiroshi Hasegawa, Tadashi Takahashi, Hiroki Sato, Noriyuki Torigoe, Toshihiko Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy |
title | Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy |
title_full | Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy |
title_fullStr | Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy |
title_full_unstemmed | Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy |
title_short | Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy |
title_sort | brother of the regulator of the imprinted site (boris) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332062/ https://www.ncbi.nlm.nih.gov/pubmed/28248963 http://dx.doi.org/10.1371/journal.pone.0171460 |
work_keys_str_mv | AT horiberyota brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT hirohashiyoshihiko brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT asanotakuya brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT mariyatasuku brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT suzukitakeshi brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT takayaakari brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT saijohiroshi brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT shionoyayosuke brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT kuboterufumi brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT nakatsugawamunehide brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT kanasekitakayuki brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT tsukaharatomohide brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT watanabekazue brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT atsuyamaeri brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT tojishingo brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT hiranohiroshi brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT hasegawatadashi brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT takahashihiroki brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT satonoriyuki brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy AT torigoetoshihiko brotheroftheregulatoroftheimprintedsiteborisvariantsubfamily6isanoveltargetoflungcancerstemlikecellimmunotherapy |